Protox files foundation patent for PORxin(TM) technology
Protox Therapeutics Inc. announced that it has filed a provisional patent application with the United States Patent and Trademark Office entitled "Modified Pore-Forming Toxins and Use Thereof". This is a foundational patent application, intended to encompass and protect several aspects of the Company's entire PORxin(TM) technology. Under this application the Company's ability to develop individual protoxin candidates to act as either "broad spectrum" anti-cancer agents or to treat specific cancer types would be protected.
The Company's ability to modify pore-forming toxins so that general or specific cleavage agents can activate them is included in the application's claims, together with other modifications that allow selective targeting of pore forming toxins to specific cells. The Company anticipates that one or more of these modified pore forming toxins may be useful in the treatment of specific forms of cancer and other diseases.
Other news from the department research and development
